News RSS Bioethics News.

05/15/2018

Why Hemophilia Patients Could Pay $1.5 Million For Gene Therapy

External Link - Source: Investor's Daily

BioMarin Pharmaceuticals (BMRN), Spark Therapeutics (ONCE) and UniQure(QURE) are racing to be the first to market with a gene therapy that treats hemophilia — a prospect that could offer revenue north of $1.5 million per patient, an analyst said Monday.

This entry was posted in Pharmaceuticals and tagged . Bookmark the permalink.